Journal of Applied Pharmaceutical Research,
Journal Year:
2024,
Volume and Issue:
12(6), P. 57 - 72
Published: Dec. 31, 2024
Background:
In
Parkinson's
disease
(PD),
a
complicated
neurodegenerative
ailment,
neurons
in
the
substantia
nigra
that
produce
dopamine
are
lost,
resulting
an
insufficiency
of
neurotransmitter
is
essential
for
regulation
voluntary
and
smooth
muscular
movements.
This
review
focuses
on
obstacle
triggering
effectiveness
traditional
PD
treatments,
which
blood-brain
barrier
(BBB),
prevents
some
therapeutic
medicines
from
reaching
brain.
It
encompasses
potential
strategy
nose-to-brain
administration
by
innovative
approaches,
including
nanoparticles,
liposomes,
dendrimers,
cell-based
carriers,
directly
delivering
drugs
nose
to
Methods:
The
methodology
involved
examining
characteristics,
advantages,
applications,
challenges
various
nanoparticles
like
SLNs,
Nanoliposomes,
Quantum
dots,
etc.,
through
meticulous
analysis
articles
PubMed
(5),
ScienceDirect
Bentham
Science
(4)
Scopus
databases
(5).
Conclusion:
concludes
emphasizing
applications
circumventing
problems
encountered
with
methods
drug
treating
PD.
detailed
study
brings
light
need
be
faced
utilizing
delivery.
Attention
directed
towards
enlightenment
advanced
carriers
target
specific
brain
regions
via
olfactory
trigeminal
routes.
reaches
brain,
bypassing
BBB.
International Journal of Nanomedicine,
Journal Year:
2025,
Volume and Issue:
Volume 20, P. 2103 - 2118
Published: Feb. 1, 2025
Lung
cancer,
a
deadly
malignancy,
often
employs
Docetaxel
(DTX)
as
chemotherapy
option.
However,
DTX
non-selective
distribution
limits
its
therapeutic
effectiveness
due
to
adverse
side
effects.
This
study
aims
develop
novel
folate-targeted
albumin
polyester
nanocarriers
(FA-DTX-APs)
encapsulating
for
precise
delivery,
enhancing
lung
cancer
treatment
efficacy.
FA-DTX-APs
were
meticulously
crafted
utilizing
the
thin-film
dispersion
technique
and
subsequently
evaluated
their
physicochemical
characteristics,
encapsulation
efficiency,
drug
release
profiles.
To
assess
biological
properties,
anti-tumor
efficacy,
biosafety
in
context
of
comprehensive
series
hemolysis
assays,
cellular
studies,
animal
experiments
conducted.
exhibit
nanovesicle
properties
with
size
(223.65
±
6.83)
nm,
potential
(26.76
3.15)
mV,
encapsulate
high
efficiency
(96.19
3.27%)
loading
capacity
(9.75
0.38%).
enable
tumor-targeted
delivery
slow
over
long
period
time,
faster
acidic
environments.
By
efficiently
targeting
entering
cells,
effectively
hinder
growth
(P
<
0.05),
demonstrating
superior
effects
biocompatibility
enhanced
safety
0.05).
introduces
FA-DTX-APs,
an
innovative
nanocarrier
characterized
by
exceptional
safety.
It
successfully
targets
cells
deliver
sustained,
slow-release
manner,
ensuring
prolonged
tumor-killing
As
such,
hold
immense
promise
nanoagent
therapy.
Biomedicine & Pharmacotherapy,
Journal Year:
2024,
Volume and Issue:
175, P. 116691 - 116691
Published: May 6, 2024
Neurodegenerative
diseases
affect
many
people
worldwide,
and
as
the
population
ages,
incidence
of
these
conditions
increases.
Alzheimer's
disease
(AD)
Parkinson's
(PD)
are
most
prevalent
neurodegenerative
disorders
worldwide.
Different
medicines
being
used
to
control
symptoms
related
conditions,
but
no
treatment
has
yet
been
approved.
Both
genetic
environmental
factors
involved
in
pathogenesis,
research
on
pathophysiological
pathways
is
still
ongoing.
The
role
subcellular
dysregulation
RNA
highlighted
studies,
strategies
focused
can
be
a
promising
approach.
Many
experiments
have
conducted
delivering
cargo
CNS
modulate
various
involved.
Yet
another
challenge
faced
effective
transport
desired
molecules
targets,
which
greatly
hindered
by
distinct
barriers
limiting
CNS,
noticeably
blood-brain
barrier
(BBB).
Nanotechnology
use
different
nano-carriers
for
delivery
nucleotides,
peptides,
proteins,
drug
currently
great
interest
carriers
help
with
better
protection
and,
result,
improve
effectiveness
cargo.
Nanocarriers
protect
susceptible
from
possible
degradation
or
destruction
their
ability
reach
brain
enhancing
BBB
penetration.
mechanisms
this
process
hypothesized.
This
review
will
go
through
therapeutic
application
AD
PD
nanocarriers
overcoming
challenges
efficacy.
ACS Omega,
Journal Year:
2024,
Volume and Issue:
9(33), P. 35223 - 35242
Published: Aug. 5, 2024
Neurodegenerative
diseases,
encompassing
conditions
such
as
Alzheimer's
disease,
Parkinson's
multiple
sclerosis,
amyotrophic
lateral
prion
and
Huntington's
present
a
growing
health
concern
human
life
expectancy
increases.
Despite
this,
effective
treatments
to
halt
disease
progression
remain
elusive
due
various
factors,
including
challenges
in
drug
delivery
across
physiological
barriers
like
the
blood-brain
barrier
patient
compliance
issues
leading
treatment
discontinuation.
In
response,
innovative
approaches
leveraging
noninvasive
techniques
with
higher
are
emerging
promising
alternatives.
This
Review
aims
synthesize
current
options
encountered
managing
neurodegenerative
while
also
exploring
modalities.
Specifically,
strategies
intranasal
administration
nanosized
systems
gaining
prominence
for
their
potential
enhance
efficacy
adherence.
Nanosized
systems,
liposomes,
polymeric
micelles,
nanoparticles,
evaluated
within
context
of
outstanding
studies.
The
advantages
disadvantages
these
discussed,
providing
insights
into
therapeutic
limitations.
Through
this
comprehensive
examination,
contributes
ongoing
discourse
surrounding
development
diseases.
Medicina,
Journal Year:
2023,
Volume and Issue:
59(6), P. 1084 - 1084
Published: June 4, 2023
As
the
search
for
modalities
to
cure
Alzheimer's
disease
(AD)
has
made
slow
progress,
research
now
turned
innovative
pathways
involving
neural
and
peripheral
inflammation
neuro-regeneration.
Widely
used
AD
treatments
provide
only
symptomatic
relief
without
changing
course.
The
recently
FDA-approved
anti-amyloid
drugs,
aducanumab
lecanemab,
have
demonstrated
unclear
real-world
efficacy
with
a
substantial
side
effect
profile.
Interest
is
growing
in
targeting
early
stages
of
before
irreversible
pathologic
changes
so
that
cognitive
function
neuronal
viability
can
be
preserved.
Neuroinflammation
fundamental
feature
involves
complex
relationships
among
cerebral
immune
cells
pro-inflammatory
cytokines,
which
could
altered
pharmacologically
by
therapy.
Here,
we
an
overview
manipulations
attempted
pre-clinical
experiments.
These
include
inhibition
microglial
receptors,
attenuation
enhancement
toxin-clearing
autophagy.
In
addition,
modulation
microbiome-brain-gut
axis,
dietary
changes,
increased
mental
physical
exercise
are
under
evaluation
as
ways
optimize
brain
health.
scientific
medical
communities
work
together,
new
solutions
may
on
horizon
or
halt
progression.
Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
17(1), P. 104 - 104
Published: Jan. 14, 2025
Monogenic
disorders
are
a
group
of
human
diseases
caused
by
mutations
in
single
genes.
While
some
disease-altering
treatments
offer
relief
and
slow
the
progression
certain
conditions,
majority
monogenic
still
lack
effective
therapies.
In
recent
years,
gene
therapy
has
appeared
as
promising
approach
for
addressing
genetic
disorders.
However,
despite
advancements
manipulation
tools
delivery
systems,
several
challenges
remain
unresolved,
including
inefficient
delivery,
sustained
expression,
immunogenicity,
toxicity,
capacity
limitations,
genomic
integration
risks,
limited
tissue
specificity.
This
review
provides
an
overview
plasmid-based
techniques
methods
currently
employed
diseases,
highlighting
they
face
exploring
potential
strategies
to
overcome
these
barriers.
Cancers,
Journal Year:
2025,
Volume and Issue:
17(5), P. 821 - 821
Published: Feb. 27, 2025
Cancer
remains
a
leading
global
health
challenge,
placing
immense
burdens
on
individuals
and
healthcare
systems.
Despite
advancements
in
traditional
treatments,
significant
limitations
persist,
including
treatment
resistance,
severe
side
effects,
disease
recurrence.
Immunotherapy
has
emerged
as
promising
alternative,
leveraging
the
immune
system
to
target
eliminate
tumour
cells.
However,
challenges
such
immunotherapy
patient
response
variability,
need
for
improved
biomarkers
limit
its
widespread
success.
This
review
provides
comprehensive
analysis
of
current
landscape
cancer
immunotherapy,
highlighting
both
FDA-approved
therapies
novel
approaches
clinical
development.
It
explores
checkpoint
inhibitors,
cell
gene
therapies,
monoclonal
antibodies,
nanotechnology-driven
strategies,
offering
insights
into
their
mechanisms,
efficacy,
limitations.
By
integrating
emerging
research
advancements,
this
underscores
continued
innovation
optimise
overcome
existing
barriers.
Small Methods,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Aug. 2, 2024
Abstract
The
systemic
delivery
of
oligonucleotide
therapeutics
to
the
brain
is
challenging
but
highly
desirable
for
treatment
diseases
undruggable
with
traditional
small‐molecule
drugs.
In
this
study,
a
set
DNA
nanostructures
prepared
and
screened
them
develop
protein
corona‐assisted
platform
therapeutics.
biodistribution
analysis
intravenously
injected
reveals
that
cube‐shaped
nanostructure
(D‐Cb)
can
penetrate
brain‐blood
barrier
(BBB)
reach
tissue.
distribution
level
D‐Cb
comparable
other
previous
nanoparticles
conjugated
brain‐targeting
ligands.
Proteomic
corona
formed
on
suggests
its
driven
by
endothelial
receptor‐targeting
ligands
in
corona,
which
mediate
transcytosis
crossing
BBB.
subsequently
used
deliver
an
antisense
(ASO)
treat
glioblastoma
multiforme
(GBM)
mice.
While
free
ASO
unable
brain,
loaded
onto
delivered
efficiently
tumor
region,
where
it
downregulates
target
gene
exerts
anti‐tumor
effect
GBM.
expected
serve
as
viable
based
formation
